Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:30:58.924Z.
Calculation as of: 2026-10-06T13:30:58.924Z.
Quote observation: 2026-10-06T13:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0793561984d12013d5f07d0ccc5da74adc08ebcd6005adbeade30d207b80f537
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$84.79M
EBITDA Yield
N/A
TTM Avg
17.90%
3Y Avg
17.90%
5Y Avg
17.90%
Market Cap
$85.60M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $84.13M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.17M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.79M | N/A | 17.90% | 17.90% | 17.90% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $87.88M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 21.39% | 23.06% | 41.09% | 38.38% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 6.81% | 6.57% | 5.72% | 4.64% |
| Citius Oncology, Inc. (CTOR)vs › | $79.78M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $88.97M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
